Millions of women diagnosed with polyendocrine metabolic ovarian syndrome (PMOS) may soon benefit from annual NHS check-ups and earlier detection, according to new preliminary recommendations from the health regulator.
The National Institute for Health and Care Excellence (NICE) suggests that women living with PMOS, previously known as polycystic ovary syndrome (PCOS), should undergo yearly evaluations to oversee the chronic hormonal disorder associated with diabetes, heart disease, fertility issues, and mental health challenges. Despite affecting approximately one in eight women, medical professionals often overlook this condition, leading to prolonged struggles in managing symptoms post-onset.
Sharon Mansfield, a committee member involved in developing the NICE draft guidance, shared her decade-long ordeal of being disregarded by doctors for irregular periods, weight concerns, and mental health issues. Mansfield expressed relief that the new guidelines could lead to earlier recognition for the estimated 3-4 million PMOS patients in the UK.
The draft guideline contains detailed instructions on identifying and diagnosing PMOS to facilitate prompt detection. NICE also emphasizes the importance of recognizing that PMOS may be more prevalent among Black, Asian, and mixed-ethnicity women during symptom assessment.
Once diagnosed, women will be offered annual health assessments to monitor symptoms and identify early signs of conditions like diabetes, enabling healthcare providers to suggest lifestyle modifications before more severe complications arise. In addition to the existing NHS support, women planning pregnancies will receive guidance on managing PMOS and information about fertility treatments, including IVF when appropriate.
The transition from PCOS to PMOS resulted from global efforts to dispel misconceptions surrounding the condition and highlight its broad “metabolic consequences” impacting overall health beyond just the ovaries.
Marie Anne Ledingham, a consultant clinical advisor for women’s and reproductive health at NICE, underscored the significance of the annual review as a crucial step towards continuous care provision. She emphasized that PMOS, a prevalent yet neglected condition, significantly influences health and well-being, and the new guideline aims to enhance care consistency, raise awareness, and promote early detection and management.
NICE is seeking feedback on the draft guideline from healthcare professionals, patients, and the public during the consultation period running from July 1 to August 11. The final PMOS guideline is slated for publication in December 2026.
